Madhu Natarajan, Takeda rare disease development head
Drawn to the idea of turning B cells into 'protein factories,' Takeda jumps into a milestone-heavy, $900M pact
Madhu Natarajan can trace his fascination with the idea of taking B cells and turning them into protein factories back 20 years, when he had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
